Article
Pharmacology & Pharmacy
Gopika Chandrababu, Merlin Varkey, Aswathy R. Devan, M. V. Anjaly, Ashok R. Unni, Lekshmi R. Nath
Summary: This study evaluated the anticancer activity of kaempferide against hepatocellular carcinoma (HCC). Kaempferide demonstrated dose-dependent cytotoxicity in three HCC cell lines and induced caspase-dependent apoptosis. In in vivo experiments, kaempferide significantly reduced tumor size and downregulated the expression of the critical tumor marker TGF-beta 1. These findings suggest that kaempferide holds promise as a potential alternative therapy for HCC.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Qian He, Rui Yan, Wanting Hou, Haibo Wang, Yali Tian
Summary: pH-responsive polyurethane prodrug micelles were designed and prepared, showing high stability and continuous drug release under acidic conditions, as well as significantly higher cellular uptake efficiency, providing a new strategy for designing novel antitumor drug delivery systems.
Article
Oncology
Robin K. Kelley, Nancy M. Joseph, Halla S. Nimeiri, Jimmy Hwang, Laura M. Kulik, Zoe Ngo, Spencer C. Behr, Courtney Onodera, Karen Zhang, Andrea G. Bocobo, Al B. Benson, Alan P. Venook, John D. Gordan
Summary: In this phase II study, the combination of temsirolimus and sorafenib demonstrated acceptable safety but did not achieve the target threshold for efficacy in hepatocellular carcinoma patients. Tumor next-generation sequencing showed mTOR pathway mutations in some patients, but these mutations were not directly associated with treatment response.
Review
Gastroenterology & Hepatology
Lorenza Rimassa, Richard S. Finn, Bruno Sangro
Summary: Single-agent immune checkpoint inhibitors (ICIs) have limited efficacy in advanced hepatocellular carcinoma (HCC) patients, and approximately 30% of patients show intrinsic resistance to ICIs. Therefore, researchers are exploring combination therapies, such as anti-angiogenic agents and other ICIs. Some trials have shown promising results and potential for clinical application. However, there are still many unanswered questions that require further research.
JOURNAL OF HEPATOLOGY
(2023)
Article
Medicine, Research & Experimental
Leyi Liang, Ling Zhao, Ying Wang, Yan Wang
Summary: The study demonstrates that BMSC-Exos-NCTD effectively promotes cellular uptake, induces cell cycle arrest, reduces tumor cell proliferation, increases apoptosis, and shows significant in vitro and in vivo antitumor effects against HCC. Additionally, BMSC-Exos exhibit in situ homing effects on tumor sites in mice and do not show body toxicity, while also repairing damaged liver tissues and promoting cell proliferation. Overall, BMSC-Exos have great potential as drug carriers for HCC treatment in combination with anticancer drugs.
MOLECULAR PHARMACEUTICS
(2021)
Article
Pharmacology & Pharmacy
Chen Fu, Jingcan Qin, Xinlong Liu, Fei Kong
Summary: In this study, galactose decorated trimethyl chitosan-camptothecin nanoparticles were successfully prepared, and it was found that the nanoparticles exhibited efficient drug release under high GSH concentration, resulting in enhanced antitumor effect and reduced systemic toxicity. This study provides potential for targeted chemotherapy in hepatocellular carcinoma.
Article
Oncology
Xiaoxia Guo, Fang Du, Qin Liu, Yan Guo, Qingbing Wang, Wei Huang, Zhongmin Wang, Xiaoyi Ding, Zhiyuan Wu
Summary: The study showed that IRE treatment increased the counts of WBC, neutrophils, and monocytes while decreasing lymphocyte count in patients. It also indicated a decrease in CD4(+) T cell subsets 1day post-IRE, with an increase in activated T cells and NK cells, and a decrease in Treg cells. Furthermore, there was a significant increase in cytotoxic CD8(+) T cells infiltration in ablative tumors in mice, along with elevated serum IFN-gamma levels in the IRE group.
Review
Medicine, General & Internal
Qiong Gao, Zhaolin Sun, Deyu Fang
Summary: Integrins, transmembrane receptors linking the extracellular matrix and actin skeleton, play key roles in tumorigenesis by regulating cell adhesion, migration, signal transduction, and gene transcription. This review focuses on the abnormal expression, activation, and signaling of integrins in human hepatocellular carcinoma (HCC), as well as their roles in the tumor microenvironment and regulation in hepatitis B virus-related HCC. Additionally, the clinical and preclinical studies of integrin-related drugs in HCC treatment are discussed.
CHINESE MEDICAL JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Kei Takuma, Shintaro Fujihara, Koji Fujita, Hisakazu Iwama, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Shima Mimura, Joji Tani, Tingting Shi, Asahiro Morishita, Hideki Kobara, Takashi Himoto, Tsutomu Masaki
Summary: This study investigates the antitumor mechanism of regorafenib on hepatocellular carcinoma (HCC) and the impact on microRNA (miRNA) expression. The results suggest that regorafenib inhibits cell proliferation and tumor growth in HCC by altering the cell cycle and miRNA expression, particularly downregulating cyclin D1.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Plant Sciences
Tianli Pei, Yifei Dai, Xue Tan, Aiai Geng, Shengrong Li, Yu Gui, Chao Hu, Jun An, Xiankuo Yu, Xilinqiqige Bao, Dong Wang
Summary: This study explores the potential anti-HCC mechanism of Yupingfeng San (YPFS) in liver cancer treatment through systems pharmacology and high throughput sequencing-based high throughput screening (HTS2) technology. The results show that YPFS possesses anti-proliferative and pro-apoptotic activities in treating HCC by inhibiting the MAPK signaling pathway. P38 is one of the critical targets of YPFS in treating HCC, which may be directly bound and inhibited by 4'-O-glucosyl-5-O-methylvisamminol, a compound derived from YPFS.
JOURNAL OF ETHNOPHARMACOLOGY
(2023)
Article
Oncology
Peiyuan Sun, Yana Qu, Yuna Wang, Jing Wang, Xuanjun Wang, Jun Sheng
Summary: This study demonstrated that the natural compound wighteone has anti-tumor effects against NSCLC with T790M mutation, inhibiting cell proliferation, suppressing the EGFR signaling pathway, causing cell cycle redistribution, and inducing cell apoptosis as mechanisms of action.
Article
Chemistry, Medicinal
Jianhui Li, Shanhao Han, Yuting Zhu, Bo Dong
Summary: In this study, a novel terpenoid compound named Halorotetin A was isolated from the ethanol extract of Halocynthia roretzi. It showed significant antitumor potential by inhibiting the proliferation of tumor cells, especially the liver carcinoma cell line. Further studies revealed that Halorotetin A affected the expression of several genes associated with hepatocellular carcinoma. These findings provide a basis for the development of antitumor drugs.
Article
Biochemistry & Molecular Biology
Ping Hu, Linzhen Hu, Yizhan Chen, Fuqian Wang, Yang Xiao, Zhou Tong, Hua Li, Ming Xiang, Qingyi Tong, Yonghui Zhang
Summary: This study explored the anti-hepatocellular carcinoma (HCC) effects and mechanism of Chaetocochin J (CJ). CJ was found to inhibit proliferation, induce cell cycle arrest, disrupt metabolism, migration, and invasion, as well as induce caspase-dependent apoptosis in HepG2 and Hep3B cells. It was also shown to inhibit the activation of the PI3K/Akt/mTOR/p70S6K/4EBP1 pathway, suppress the expression of HIF-1 alpha, disrupt the binding of HIF-1 alpha/p300, and subsequently inhibit the expression of target genes.
BIOORGANIC CHEMISTRY
(2023)
Review
Gastroenterology & Hepatology
Byung Min Lee, Jinsil Seong
Summary: ICIs have shown clinical efficacy against most solid cancers, and recent success in combination therapy with targeted agents in hepatocellular carcinoma has accelerated the search for novel combination strategies. Additionally, radiotherapy can be combined with ICIs to modulate the tumor immune microenvironment.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Medicine, General & Internal
Wesley C. C. Burkett, Ziyi Zhao, Meredith A. A. Newton, Wenchuan Sun, Boer Deng, Angeles Alvarez Secord, Chunxiao Zhou, Victoria Bae-Jump
Summary: The combination of IPAT and carboplatin showed better anti-tumor activity in USC cells compared to IPAT or carboplatin alone. The combination treatment led to reduced proliferation, induced apoptosis and caused cellular stress. In addition, it also reduced cell adhesion and inhibited cell invasion.
ANNALS OF MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Leonard Depotte, Juliette Palle, Cosimo Rasola, Chloe Broudin, Vlad-Adrian Afrasanie, Antoine Mariani, Aziz Zaanan
Summary: Advanced gastric adenocarcinoma is a disease with poor prognosis. In recent years, new drugs, such as trastuzumab for HER2-positive tumors, ramucirumab alone or in combination with paclitaxel, and trifluridine-tipiracil, have improved patient survival. Other drugs, including monoclonal antibodies and targeted therapies, are also being evaluated.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2024)